Phillip S. Pang, Ahmad Kamal, Jeffrey S. Glenn – 28 August 2009 – The purpose of this study was to determine the effect of donor race on the outcome of black patients with chronic hepatitis C infection who undergo liver transplantation. The records for deceased donor liver transplants that occurred in the United States between January 1998 and December 2007 were obtained from the United Network for Organ Sharing. 26,212 records contained sufficient data to be included in the analysis.

Tara Rubinas, Evan Dellon, Gabriella Henel – 28 August 2009

Shui‐Ming Jiang, Guang‐Wen Zhou, Rui Zhang, Cheng‐Hong Peng, Ji‐Qi Yan, Liang Wan, Chuan Shen, Hao Chen, Qing‐Yu Li, Bai‐Yong Shen, Hong‐Wei Li – 28 August 2009 – The aim of this study was to investigate the changes in splanchnic hemodynamics after LDLT and their relationship with graft regeneration. Eighteen patients with LDLT December 2006 and June 2008 were enrolled, and color Doppler ultrasonography was performed preoperatively and on postoperative days (PODs) 1, 3, 5, 7, 30, and 90 after transplantation.

Maria D. P. Hernandez, Lennox J. Jeffers – 28 August 2009

Mark J. Hill, Michael Hughes, Tun Jie, Melissa Cohen, John Lake, William D. Payne, Abhinav Humar – 28 August 2009 – Partial graft liver recipients with graft weight/recipient weight (GW/RW) ratios < 0.8% are thought to have a higher incidence of postoperative complications, including small‐for‐size syndrome (SFSS). We analyzed a cohort of such recipients and compared those with GW/RW < 0.8% to those with GW/RW ≥ 0.8%.

Roberto J. Firpi, Virginia Clark, Consuelo Soldevila‐Pico, Giuseppe Morelli, Roniel Cabrera, Cynthia Levy, Victor I. Machicao, Chen Chaoru, David R. Nelson – 28 August 2009 – Hepatitis C after liver transplantation leads to graft cirrhosis in up to 30% of patients within 5 years, but limited data exist regarding the clinical course of cirrhosis after transplantation. The aims of this study were to report the natural history of hepatitis C cirrhosis after liver transplantation and to identify risk factors for decompensation and survival.

Yuan Heng Mo, Po Chin Liang, Ming Chih Ho, Po Huang Lee, Fu Shan Jaw, Steven Shinn‐Forng Peng – 28 August 2009 – The purpose of this study was to investigate the effectiveness of the combined use of intravenous morphine and intramuscular glucagon in improving magnetic resonance cholangiopancreatography (MRCP) image quality in donors for living‐related liver transplantation. Sixteen healthy donor candidates underwent an MRCP study.

Dipanjan Chanda, Chul Ho Lee, Yong‐Hoon Kim, Jung‐Ran Noh, Don‐Kyu Kim, Ji‐Hoon Park, Jung Hwan Hwang, Mi‐Ran Lee, Kyeong‐Hoon Jeong, In‐Kyu Lee, Gi Ryang Kweon, Minho Shong, Goo‐Taeg Oh, John Y. L. Chiang, Hueng‐Sik Choi – 27 August 2009 – Plasminogen activator inhibitor type I (PAI‐1) is a marker of the fibrinolytic system and serves as a possible predictor for hepatic metabolic syndromes. Fenofibrate, a peroxisome proliferator‐activated receptor α (PPARα) agonist, is a drug used for treatment of hyperlipidemia.

Rui Xiang Lei, Hong Shi, Xiao Mou Peng, Yin Hong Zhu, Jie Cheng, Gui Hua Chen – 27 August 2009 – Hepatitis B e antigen (HBeAg) is a viral strategy of immune response evasion associated with hepatitis B virus (HBV) persistence. Spontaneous HBeAg seroconversion is usually accompanied by liver disease remission. Unfortunately, this goal is difficult to achieve and requires expensive and time‐consuming treatment. Furin, a proprotein convertase, is involved in HBeAg maturation and is therefore a potential therapeutic target or indicator for predicting disease progression and antiviral response.

Haeryoung Kim, Bong‐Kyeong Oh, Massimo Roncalli, Chanil Park, So‐Mi Yoon, Jeong Eun Yoo, Young Nyun Park – 27 August 2009 – Large liver cell change (LLCC) refers to microscopic lesions often found in various chronic liver diseases; however, its nature is still controversial. Thirty‐four formalin‐fixed and 19 fresh frozen hepatitis B virus (HBV)‐related cirrhosis samples were examined for the presence of LLCC, small liver cell change (SLCC), and hepatocellular carcinoma (HCC).